# US 2023/0066890 A1 · Treatment of internal disc disruption and connective tissue injuries

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0066890 A1
- Document ID: US20230066890A1
- Status: Published application
- Kind: A1
- Application number: 17/656,926
- Filed: 2022-03-29
- Published: 2023-03-02
- Earliest claimed: 2021-09-02
- Inventors: Bjorn Eek
- Web page: https://patentgrep.com/patent/US20230066890A1

## CPC

- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 31/728: Hyaluronic acid
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 47/02: Inorganic compounds
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/38: Cellulose; Derivatives thereof
- A61L 27/20: Polysaccharides
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 2300/414: Growth factors
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/38: for reconstruction of the spine, vertebrae or intervertebral discs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

This disclosure relates to treating internal disc disruption or a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-β1) or transforming growth factor beta 2 (TGF-β2), fibroblast growth factor (FGF), and a pharmaceutically acceptable excipient or a secondary agent.

## Claims

### Claim 1

A therapeutic composition comprising Transforming growth factor beta 1 (TGF-β1) or Transforming growth factor beta 1 (TGF-β2), Fibroblast growth factor (FGF), water, and at least 2 of the following excipients or secondary agents: dextrose, lidocaine, chondroitin, carboxymethyl cellulose, glucosamine, hyaluronic acid, and a buffer.

### Claim 2 (depends on 1)

The therapeutic composition of claim 1, comprising TGF-β1.

### Claim 3 (depends on 1)

The therapeutic composition of claim 1, comprising TGF-β2.

### Claim 4 (depends on 1)

The therapeutic composition of claim 1, comprising at least 3 of the following excipients or secondary agents: dextrose, lidocaine, chondroitin, carboxymethyl cellulose, glucosamine, hyaluronic acid, and the buffer.

### Claim 5 (depends on 1)

The therapeutic composition of claim 1, comprising at least 4 of the following excipients or secondary agents: dextrose, lidocaine, chondroitin, carboxymethyl cellulose, glucosamine, hyaluronic acid, and the buffer.

### Claim 6 (depends on 1)

The therapeutic composition of claim 1, comprising at least 5 of the following excipients or secondary agents: dextrose, lidocaine, chondroitin, carboxymethyl cellulose, glucosamine, hyaluronic acid, and the buffer.

### Claim 7 (depends on 1)

The therapeutic composition of claim 1, comprising at least 6 of the following excipients or secondary agents: dextrose, lidocaine, chondroitin, carboxymethyl cellulose, glucosamine, hyaluronic acid, and the buffer.

### Claim 8 (depends on 1)

The therapeutic composition of claim 1, comprising dextrose, lidocaine, chondroitin, carboxymethyl cellulose, glucosamine, hyaluronic acid, and the buffer.

### Claim 9 (depends on 1)

The therapeutic composition of claim 1, comprising about 1 ng/mL to 20 ng/mL of TGF-β1.

### Claim 10 (depends on 1)

The therapeutic composition of claim 1, comprising about 1 ng/mL to 20 ng/mL of TGF-β2.

### Claim 11 (depends on 1)

The therapeutic composition of claim 1, comprising about 50 ng/mL to 200 ng/mL of FGF.

### Claim 12 (depends on 1)

The therapeutic composition of claim 1, comprising about 5% to about 15% dextrose.

### Claim 13 (depends on 1)

The therapeutic composition of claim 1, comprising about 0.25% to about 1% lidocaine.

### Claim 14 (depends on 1)

The therapeutic composition of claim 1, comprising about 0.5% to about 2% chondroitin sulfate.

### Claim 15 (depends on 1)

The therapeutic composition of claim 1, comprising about 1% to about 6% glucosamine HCl.

### Claim 16 (depends on 1)

The therapeutic composition of claim 1, comprising about 0.05% to about 6% hyaluronic acid.

### Claim 17 (depends on 1)

The therapeutic composition of claim 1, which is buffered to a pH of about 6 to about 7, wherein the buffer comprises a phosphate buffer.
